Rezultaty - Allison Crosby‐Thompson
- Rezultaty 1 - 4 Rezultaty od 4
-
1
Radiation for diffuse large <scp>B</scp>‐cell lymphoma in the rituximab era: Analysis of the <scp>N</scp>ational <scp>C</scp>omprehensive <scp>C</scp>ancer <scp>N</scp>etwork lymph... od Bouthaina S. Dabaja, Ann Vanderplas, Allison Crosby‐Thompson, Gregory A. Abel, Myron S. Czuczman, Jonathan W. Friedberg, Leo I. Gordon, Mark Kaminski, Joyce C. Niland, Michael Millenson, Auayporn Nademanee, Andrew D. Zelenetz, Ann S. LaCasce, Maria Alma Rodriguez
Wydane 2014Artigo -
2
Transformed non‐Hodgkin lymphoma in the rituximab era: analysis of the <scp>NCCN</scp> outcomes database od Makiko Ban‐Hoefen, Ann Vanderplas, Allison Crosby‐Thompson, Gregory A. Abel, Myron S. Czuczman, Leo I. Gordon, Mark Kaminski, Jennifer L. Kelly, Michael Millenson, Auayporn Nademanee, Maria Alma Rodriguez, Andrew D. Zelenetz, Joyce C. Niland, Ann S. LaCasce, Jonathan W. Friedberg
Wydane 2013Artigo -
3
KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma od Katherine N. Cahill, Howard R. Katz, Jing Cui, Juying Lai, Shamsah Kazani, Allison Crosby‐Thompson, Denise Garofalo, Mario Castro, Nizar N. Jarjour, Emily DiMango, Serpil C. Erzurum, Jennifer Trevor, Kartik Shenoy, Vernon M. Chinchilli, Michael E. Wechsler, Tanya M. Laidlaw, Joshua A. Boyce, Elliot Israel
Wydane 2017Artigo -
4
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era od Zheng Zhou, Laurie H. Sehn, Alfred Rademaker, Leo I. Gordon, Ann S. LaCasce, Allison Crosby‐Thompson, Ann Vanderplas, Andrew D. Zelenetz, Gregory A. Abel, Maria Alma Rodriguez, Auayporn Nademanee, Mark Kaminski, Myron S. Czuczman, Michael Millenson, Joyce C. Niland, Randy D. Gascoyne, Joseph M. Connors, Jonathan W. Friedberg, Jane N. Winter
Wydane 2013Artigo
Narzędzie wyszukiwania:
Podobne hasła
Internal medicine
Medicine
Lymphoma
Oncology
Rituximab
Gastroenterology
International Prognostic Index
Airway
Alternative medicine
Anesthesia
Asthma
Bronchial hyperresponsiveness
CHOP
Chemotherapy
Clinical trial
Confidence interval
Cyclophosphamide
Diffuse large B-cell lymphoma
Hazard ratio
Hodgkin lymphoma
Imatinib
Imatinib mesylate
Immunology
Lung
Mast cell
Methacholine
Multivariate analysis
Myeloid leukemia
Pathology
Placebo